The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system

Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial resistance & infection control 2021-03, Vol.10 (1), p.45-13, Article 45
Main Authors: Said, Dunja, Willrich, Niklas, Ayobami, Olaniyi, Noll, Ines, Eckmanns, Tim, Markwart, Robby
Format: Article
Language:English
Subjects:
Acinetobacter baumannii complex
Analysis
Antibacterial agents
Antibiotics
Antimicrobial agents
Antimicrobial resistance
ARS
Carbapenem resistance
Disease control
Drug resistance
Drug resistance in microorganisms
Epidemiology
Gender
Health aspects
Hospitals
Infections
Intensive care
Laboratories
Outpatient care facilities
Pathogens
Patients
Public health
Risk factors
Surveillance
Urine
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948 clinical A. baumannii complex isolates using 2014 to 2018 data from the German Antimicrobial Resistance Surveillance system. We applied descriptive statistics and uni- and multivariable regression analyses to investigate carbapenem resistance in A. baumannii complex isolates. The proportion of carbapenem resistance in clinical A. baumannii complex isolates declined from 7.6% (95% confidence interval [95% CI] 4.4-12.7%) in 2014 to 3.5% (95% CI 2.5-4.7%) in 2018 (adjusted OR [aOR] 0.85 [95% CI 0.79-0.93, p ≤ 0.001]). Higher mean CRABC proportions for 2014 to 2018 were observed in secondary care hospitals (4.9% [95% CI 3.2-7.5%], aOR 3.6 [95% CI 2.4-5.3, p ≤ 0.001]) and tertiary care hospitals (5.9% [95% CI 3.0-11.2%], aOR 5.4 [95% CI 2.9-10.0, p ≤ 0.001) compared to outpatient clinics (1.3% [95% CI 1.1-1.6%]). CRABC proportions in hospitals varied between German regions and ranged between 2.4% (95% CI 1.6-3.5%) in the Southeast and 8.8% (95% CI 4.2-17.3%) in the Northwest. Lower CRABC proportions were observed in younger patients (
ISSN:2047-2994
2047-2994
DOI:10.1186/s13756-021-00909-8